Since the 2009 approval of bepotastine besilate ophthalmic solution 1.5% for ophthalmic use in the United States, further analysis of clinical trial data and new information from additional studies have revealed more about the drug's clinical utility.
Loteprednol etabonate ophthalmic suspension 0.2% is a safe and effective first-line therapy for the treatment of seasonal and perennial allergic conjunctivitis.
The FDA has delayed approval of Alimera Sciences' investigational fluocinolone acetonide intravitreal insert for the treatment of diabetic macular edema associated with diabetic retinopathy and requested two additional clinical trials.
The pivotal study of a sustained-release dexamethasone intravitreal implant showed that it was a safe, effective option for the treatment of noninfectious intermediate and posterior uveitis.
A novel ocular surface interferometer may help physicians more accurately diagnose and monitor lipid-deficient evaporative dry eye.
Should anticoagulants be discontinued before oculofacial surgery?
Ophthalmic surgical instrument manufacturers and distributors work in a constantly evolving and increasingly global marketplace, and in late 2009, are meeting challenges posed by new procedures and changing government regulations.
An investigational compound for the treatment of dry eye disease consisting of a proprietary formulation of sodium hyaluronate ophthalmic solution 0.18% (Vismed, Lantibio Inc.) was shown to be safe and effective in a multicenter phase III trial conducted in the United States. A new drug application has been filed for the solution, which is already marketed in parts of Europe and Asia as a viscoelastic lubricant eye drop.
New software (MatchedFlicker, EyeIC) uses time series retinal photographs to convert change into motion and could improve the accuracy and speed of detecting glaucomatous progression.
Longer duration of use of monotherapy with prostaglandin analogues may be associated with lower annual costs of glaucoma treatment because adjunctive therapy is one of the primary factors affecting the cost of care, suggest findings of a retrospective analysis of a pharmacy claims database.